

## Survival Outcomes Related to Treatment Modalities in Patients with Oropharyngeal Squamous Cell Carcinoma

**Authors :** Danni Cheng

**Abstract :** Purpose: Surgically inclusive treatment (SIT) is the major treatment for oropharyngeal squamous cell carcinoma (OPSCC) in Eastern countries, while nonsurgical treatments (NSTs) are the priority treatment in Western countries. The preferred treatments for OPSCC patients remain debated. Methods: A total of 153 consecutive OPSCC cases diagnosed between 2009 and 2019 in WCH, and 15,400 OPSCC cases from SEER database (2000-2017) were obtained. Clinical characteristics, treatments, and survival outcomes were retrospectively collected. We conducted Kaplan-Meier curves univariate and multivariate analysis to compare the prognosis of OPSCC patients in WCH, SEER Asian, and SEER all ethnic population by different treatment modalities, HPV status, ages, and TNM stages. Results: The 5-year overall survival rate was 59% in WCH, 64% in the SEER all ethnic and 67% in SEER Asian group. In both univariate and multivariate analysis, SIT was observed as a consistent benefit factor for OPSCC patients in all three populations when classified by genders, tumor stages, and HPV status. Patients who underwent SIT had significantly better survival outcomes than those who received NSTs in WCH, SEER Asian, and SEER all ethnic groups. HPV positive status was the beneficial factor of OPSCC patients in all three groups. Besides, male patients had worse survival outcomes in both WCH and SEER Asian group, whereas male patients had better outcomes in the SEER all ethnic group. Conclusion: In contrast to nowadays NSTs are the first-line therapies for OPSCC, our ten-year real-world data and SEER data indicated that OPSCC patients who underwent SIT had better prognosis than NSTs.

**Keywords :** OPSCC, survival outcome, SEER, treatment modalities

**Conference Title :** ICHNO 2022 : International Conference on Head and Neck Oncology

**Conference Location :** Barcelona, Spain

**Conference Dates :** October 20-21, 2022